Analyst Ratings For BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
Today, JMP Securities reiterated its Outperform rating on BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) with a price target of $16.00.
There are 6 Buy Ratings, 3 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) is Buy with a consensus target price of $10.9286 per share, a potential 43.99% upside.
Some recent analyst ratings include
- 9/5/2018-BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) had its Outperform rating reiterated by JMP Securities with a $16.00 price target
- 8/13/2018-BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) had its Buy rating reiterated by HC Wainwright with a $13.00 price target
- 8/9/2018-BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) had its Buy rating reiterated by Jefferies Financial Group with a $8.50 price target
- 8/8/2018-BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has coverage initiated with a Overweight rating and $9.00 price target
- 8/7/2018-BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) had its Buy rating reiterated by Royal Bank of Canada with a $9.00 price target
- 7/17/2018-BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) gets upgraded to Neutral by Bank of America
- 6/28/2018-BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) had its Neutral rating reiterated by Seaport Global Securities
About BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The company markets peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza in the United States and Canada under the name RAPIVAB, in Japan and Taiwan as RAPIACTA, and in Korea as PERAMIFLU; and Mundesine, an oral purine nucleoside phosphorylase inhibitor to treat cancer in Japan. It also develops BCX7353 and second generation kallikrein inhibitors, which are oral serine protease inhibitors targeting plasma kallikrein for hereditary angioedema; BCX9250 and BCX9499, which are activin receptor-like kinase-2 inhibitors for fibrodysplasia ossificans progressive; and Galidesivir, a RNA dependent-RNA polymerase inhibitor to treat RNA viruses. The company has collaborations and in-license relationships with U.S. Department of Health and Human Services; National Institute of Allergy and Infectious Diseases; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; and The University of Alabama at Birmingham. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Recent Trading Activity for BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
Shares of BioCryst Pharmaceuticals, Inc. closed the previous trading session at 7.59 up +0.43 6.01% with 7.62 shares trading hands.
